Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
Earnings Data
Report Date
Apr 07, 2026Before Open (Not Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.01Last Year’s EPS
-0.01Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and significant advancements in R&D, including a transformative deal with MSD and promising clinical data for EVX-01. However, market uncertainties and extended evaluation periods for deals, like EVX-B2, present challenges. Overall, the achievements and financial stability significantly outweigh the challenges.Company Guidance
MSD Transformative Deal
Evaxion's first ever in-licensing of an AI discovered vaccine candidate by a major pharma company, MSD, exercised their option on EVX-B3. This included a $7.5 million exercise fee, extending the company's cash runway significantly and potentially up to $592 million in future revenue.
Strong Financial Performance
The company extended its cash runway into the second half of 2027, strengthened equity with a USD 31.8 million improvement, and recorded a quarterly operational gain for the first time. The balance sheet showed a strong cash balance of USD 10.6 million by the end of the quarter.
Clinical Efficacy of EVX-01
Presented highly encouraging two-year clinical outcome data from the EVX-01 Phase II study with a 75% objective overall response rate and a 34% conversion rate, indicating significant potential for long-term control of melanoma.
Enhanced AI-Immunology Platform
The platform was expanded with a new automated vaccine design module, significantly reducing design time and accelerating development timelines, ensuring optimal sequence and conformation of vaccine targets.
EVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $5.66 | $6.26 | +10.60% |
Aug 14, 2025 | $3.04 | $2.86 | -5.92% |
May 27, 2025 | $1.88 | $2.36 | +25.53% |
Apr 01, 2025 | $1.85 | $1.66 | -10.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Evaxion Biotech (EVAX) report earnings?
Evaxion Biotech (EVAX) is schdueled to report earning on Apr 07, 2026, Before Open (Not Confirmed).
What is Evaxion Biotech (EVAX) earnings time?
Evaxion Biotech (EVAX) earnings time is at Apr 07, 2026, Before Open (Not Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVAX EPS forecast?
EVAX EPS forecast for the fiscal quarter 2025 (Q4) is -0.01.